Summary

Hematologic malignancies have a cluster of symptoms that differ in degree from solid tumors. Fatigue, depression, delirium, treatment-related mucositis, and treatment-related pain are common symptoms. These symptoms can occur at early stages of disease, can persist through remission, and will require both nonpharmaco-logic and pharmacologic management. Involvement of palliative therapy early in the course of disease can minimize suffering from multiple symptoms while the patient undergoes disease-modifying antitumor therapy.

14. Von Roenn JH, Cleeland CS, Gonin R, et al: Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119(2):121-126, 1993.

15. Shvartzman P, Friger M, Shani A, et al: Pain control in ambulatory cancer patientes - can we do better? J Pain Symptom Management 26(2):716-722, 2003.

16. Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2):l29-l38, l994.

17. Twycross R, Harcourt J, Bergl S: A survey of pain in patients with advanced cancer. J Pain Symptom Management 12(5):273-282, 1996.

18. Twycross R: Cancer pain classification. Acta Anaesthesiol Scand 41(1 Pt 2):141-145, 1997.

19. Hanks GW, Conno F, Cherny N, et al: Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Can 84(5):587-593, 2001.

20. Walsh D: Pharmacological management of cancer pain. Sem Onc 27(1):45-63, 2000.

21. Cherny N, Ripamonti C, Pereira J, et al: Strategies to manage the adverse effects of oral morphine: an evidence-based report. JCO 19(9):2542-2554, 2001.

22. Mercadante S: Opioid rotation for cancer pain. Cancer 86:1856-1866, 1999.

23. Kochhar R, LeGrand, SB, Walsh D, et al: Opioids in cancer pain: common dosing errors. Oncology 17(4):571-575, 2003.

24. Davis MP, Walsh D: Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynam-ics, drug interactions and protocols of administration. Supportive Care Cancer 9:73-83, 2001.

25. Davis MP, Varga J, Dickerson D, et al: Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Supportive Care Cancer 11:84-92, 2003.

26. Donnelly S, Davis MP, Walsh D, et al: Morphine in cancer pain management: a practical guide. Supportive Care Cancer 10:13-35, 2002.

27. Menten J, Desmedt M, Lossignol D, et al: Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin 18(8):488-498, 2002.

28. Sarhill N, Walsh D, Nelson KA: Hydromorphone: pharmacology and clinical applications in cancer patients. Supportive Care Cancer 9:84-96, 2001.

29. Pasternak GW: Insights into mu opioid pharmacology. The role of mu opioid receptor subtypes. Life Sci 68:2213-2219, 2001.

30. Dudeney S, Lieberman IH, Reinhardt M-K, et al: Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. JCO 20(9):2382-2387, 2002.

31. Saito R, Takano Y, Kamiya H: Roles of substance P and KK1 receptor in the brainstem in the development of emesis. JPharm Sci 91:87-94, 2003.

32. Koga T, Fukuda H: Descending pathway from the central pattern generator of vomiting. Neuroreport 8(11):2587-2590, 1997.

33. Martin CG, Rubenstein EB, Elting LS, et al: Measuring chemotherapy-Induced nausea and emesis. Cancer 98:645-655, 2003.

34. Ihbe-Heffinger A, Ehlken B, Bernard R, et al: The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Onc 15:526-536, 2004.

35. Spitzer TR, Grunberg SM, Dicato MA: Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting. SCC 6:233-236, 1998.

36. Chevalier-Evain V, Bonneterre J, Adenis A, et al: Loss of efficacy of ondansetron-dexamethasone during success courses in female patients receiving high-dose cisplatin. Bull Cancer 81(3):219-222, 1994.

37. Navari RM: Pathogenesis-Based treatment of chemotherapy-induced nausea and vomiting - two new agents. Supp Onc 1(2):89-103.

38. Bonneterre J, Hecquet B: Granisetron (IV) compared with ondansetron (IV plus oral) in prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bull Cancer 82(12):1038-1043, 1995.

39. Lonback MK: Why do we need another antiemetic? Just ask. JCO 21(22):4077-4080, 2003.

40. De Wit R, Herrstedt J, Rapoport B, et al: Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. JCO 21(22):4105-4111, 2003.

41. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neu-rokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin- the Aprepitant Protocol 052 study group. JCO 21(22):4112-4119, 2003.

42. Knox JJ, Puodziunas ALV, Feld R: Chemotherapy-Induced oral mucosistis. Drugs Aging 17(4):257-267, 2000.

43. Cella D, Pulliam J, Fuchs H, et al: Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98:406-412, 2003.

44. Kostler WJ, Hejna M, Wenzel C, et al: Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Can J Clin 51:290-315, 2001.

45. Plevova P: Prevention and treatment of chemotherapy and radiotherapy induced oral mucositis: a review. Oral Onc 35:453-470, 1999.

46. Clarkson JE, Worthington HV, Eden OB: Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 3:CD000978, 2003.

47. Worthington HV, Clarkson JE: Prevention of oral mucositis and oral candidiasis for patients with cancer treated with chemotherapy: cochrane systematic review. J Dent Educ 66(8):903-911, 2002.

48. Worthington HV, Clarkson JE, Eden OB: Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 1:CD001973, 2002.

49. Donnelly JP, Bellm LA, Epstein JB, et al: Antimicrobial therapy to prevent or treat oral mucositis. Lancet 3:405-412, 2003.

50. Curt GA: Fatigue in cancer. Br Med J 322:1560, 2001.

51. Curt GA, Breitbart W, Cella D, et al: Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncology 5:353-360, 2000.

52. Curt GA: The impact of fatigue on quality of life in oncology patients. Sem Hematol 37(4 suppl 6):14-17.

53. Stasi R, Abriani L, Beccaglia P, et al: Cancer-related fatigue Evolving concepts in evaluation and treatment. Cancer 98:1786-1801, 2003.

54. Respini D, Jacobsen PB, Thors C, et al: The prevalence and correlates of fatigue in older cancer patients. Crit Rev Onc-Hema 47(3):273-279.

55. Vogelzang NJ, Breitbart W, Cella D, et al: Patient, care-giver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Sem Hema 34(3, suppl 2):4-12, 1997.

56. Langeveld N, Ubbink M, Smets E: 'I don't have any energy': the experience of fatigue in young adult survivors of childhood cancer. Eur J Onc Nurs 4(1):20-28, 2000.

57. Portenoy RK, Itri L: Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4:1-10, 1999.

58. Berger A: Treating fatigue in cancer patients. Oncologist 8(suppl 1):10-14, 2003.

59. Barnes EA, Bruera E: Fatigue in patients with advanced cancer: A review. Int J Gyn Can 12:424-428, 2002.

60. Mock V: Fatigue management: evidence and guidelines for practice. Cancer 92(6, suppl):1699-1707, 2001.

61. Tralongo P, Respini D, Ferra AF: Fatigue and aging. Crit Rev Onc-Hema 48(suppl):S57-S64, 2003.

62. Escalante CP: Treatment of cancer-related fatigue: an update. SCC 11:79-83, 2003.

63. Penedo FJ, Schneiderman N, Dahn JR, et al: Physical activity interventions in the elderly: cancer and comor-bidity. Cancer Invest 22(1):51-67, 2004.

64. Irwin ML, Ainsworth BE: Physical activity interventions following cancer diagnosis: methodologic challenges to delivery and assessment. Cancer Invest 22(1):30-50, 2004.

65. Lloyd-Williams M: Difficulties in diagnosing and treating depression in the terminally ill cancer patient. Postgrad Med J 76(899):555-558, 2000.

66. Maguire P: The use of antidepressants in patients with advanced cancer. SCC 8:265-267, 2000.

67. Block SD: Assessing and managing depression in the terminally ill patient. Ann Int Med 132(3):209-218, 2000.

68. Tiernan E, Casey P, O'Boyle C, et al: Relations between desire for early death, depressive symptoms and antidepressant prescribing in terminally ill patients with cancer. J Roy Soc Med 95:386-390, 2002.

69. Lloyd-Williams M: Screening for depression in palliative care patients: a review. Eur J Can Care 10:31-5, 2001.

70. Lloyd-Williams M, Riddleston H: The stability of depression scores in patients who are receiving palliative care. JPSM 24(6):593-597, 2002.

71. Berney A, Stiefel F, Mazzocato, et al: Psychopharmacol-ogy in supportive care of cancer: a review for the clinician. SCC 8:278-286, 2000.

72. Pessin H, Potash M, Breitbart W: Diagnosis, assessment, and treatment of depression in palliative care. In: Lloyd-Williams M (ed.) Psychosocial Issues in Palliative Care, 1st edn. Oxford, Oxford University Press; 2003.

73. Sharpe M, Strong V, Allen K, et al: Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Can 90:314-320, 2004.

74. Lloyd-Williams M, Friedman T, Rudd N: A survey of antidepressant prescribing in the terminally ill. Pall Med 13:243-248, 1999.

75. Inouye SK: Prevention of delirium in hospitalized older patients: risk factors and targeted strategies. Ann Med 32(4):257-263, 2000.

76. Pereira J, Bruera E: Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants. J Pall Med 4(1):15-21, 2001.

77. Bruera E, Neumann CM: The uses of psychotropics in symptom management in advanced cancer. Psyco-Onc 7:346-358, 1998.

78. Fann JR, Roth-Roemer S, Burington BE, et al: Delirium in patients undergoing hematopoietic stem cell transplantation: Incidence and pretransplantation risk factors. Cancer 95:1971-1981, 2002.

79. Fann JR, Sullivan AK: Delirium in the course of cancer treatment. Sem Clin Neuropsychiatry 8(4):217-228, 2003.

80. Brown TM, Boyle MF: ABC of psychological medicine Delirium. Br Med J 325:644-647, 2002.

81. Ljubisavljevic V, Kelly B: Risk factors for development of delirium among oncology patients. Gen Hosp Psych 25:345-352, 2003.

82. Tuma R, DeAngelis LM: Altertered mental status in patients with cancer. Arch Neurol 57(12):1727-1731, 2000.

83. Dunlop RJ, Campbell CW: Cytokines and advanced cancer. JPSM 20(3):214-232, 2000.

84. Walker MC: Diagnosis and treatment of nonconvulsive status epilepticus. CNS Drugs 15(12):931-939, 2001.

85. Martinez-Rodriguez JE, Barriga FJ, Santamaria J, et al: Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med 111(2):115-119, 2001.

86. Markand ON: Pearls, perils, and pitfalls in the use of the electroencephalogram. Sem Neurol 23(1):7-46, 2003.

87. Inouye SK, Bogardus ST Jr, Charpentier PA, et al: A mul-ticomponent intervention to prevent delirium in hospitalized older patients. NEJM 340(9):669-676, 1999.

88. Weber JB, Coverdale, JH, Kunik ME: Delirium: current trends in prevention and treatment. Int Med J 34:115-121, 2004.

89. Schwartz TL, Masand PS: The role of atypical antipsy-chotics in the treatment of delirium. Psychosomatics 43(3):171-174, 2002.

90. Passik SC, Cooper M: Complicated delirium in a cancer patient successfully treated with olanzapine. JPSM 17:219-223, 1999.

91. Seneff MG, Mathews RA: Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharm 29(7/8):690-693, 1995.

92. Meagher DJ: Delirium: optimising management. Br Med J 322:144-149, 2001.

93. Lawlor PG, Gagnon B, Mancini I, et al: Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Int Med 160(6):786-794, 2000.

94. McClain CS, Rosenfeld B, Breitbart W: Effect of spiritual well-being on end-of-life despair in terminally ill cancer patients. Lancet 361:1603-1607, 2003.

95. Clark PA, Drain M, Malone MP: Addressing patients' emotional and spiritual needs. Jt Comm J Qual Saf 29(12):659-670, 2003.

96. Lunn JS: Spiritual care in multi-religious context. J Pall Care Pharm 17(3/4):153-166, 2003.

97. Keeley Maureen P: Final conversations: survivors' memorable messages concerning religious faith and spirituality. Health Comm 16(1):87-104.

98. Proulx K, Jacelon C: Dying with dignity: the good patient versus the good death. Am J Hosp Pall Care 21(2):116-120.

99. Davis MP, Frandsen J, Dickerson D, et al: Prescribing for the dying patient: principles and practice. JTO 1(1):32-45, 2002.

100. Nelson KA, Walsh D, Behrens C, et al: The dying cancer patient. Sem Onc 27(1):84-89, 2000.

101. Ellershaw J, Ward C: Care of the dying patient: the last hours or days of life. Br Med J 326:30-34, 2003.

Natural Depression Cures

Natural Depression Cures

Are You Depressed? Heard the horror stories about anti-depressants and how they can just make things worse? Are you sick of being over medicated, glazed over and too fat from taking too many happy pills? Do you hate the dry mouth, the mania and mood swings and sleep disturbances that can come with taking a prescribed mood elevator?

Get My Free Ebook


Post a comment